| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
|
JAMA
|
2010
|
9.26
|
|
2
|
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
|
JAMA
|
2012
|
8.94
|
|
3
|
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
|
JAMA
|
2002
|
5.56
|
|
4
|
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
Clin Infect Dis
|
2008
|
5.20
|
|
5
|
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
|
Clin Infect Dis
|
2003
|
4.51
|
|
6
|
The challenge of HIV-1 subtype diversity.
|
N Engl J Med
|
2008
|
3.88
|
|
7
|
HIV vaccine research: the way forward.
|
Science
|
2008
|
3.86
|
|
8
|
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
|
JAMA
|
2004
|
3.74
|
|
9
|
Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries.
|
Int J Health Geogr
|
2009
|
2.87
|
|
10
|
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
|
Clin Infect Dis
|
2009
|
2.75
|
|
11
|
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
|
J Infect Dis
|
2010
|
2.15
|
|
12
|
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
|
J Infect Dis
|
2002
|
1.70
|
|
13
|
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.
|
J Infect Dis
|
2011
|
1.55
|
|
14
|
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
|
Antimicrob Agents Chemother
|
2003
|
1.53
|
|
15
|
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
|
Clin Infect Dis
|
2004
|
1.52
|
|
16
|
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
|
J Infect Dis
|
2003
|
1.51
|
|
17
|
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
|
J Acquir Immune Defic Syndr
|
2004
|
1.48
|
|
18
|
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
|
Clin Infect Dis
|
2004
|
1.39
|
|
19
|
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
|
J Infect Dis
|
2003
|
1.38
|
|
20
|
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
|
J Antimicrob Chemother
|
2004
|
1.34
|
|
21
|
Ebola and quarantine.
|
N Engl J Med
|
2014
|
1.32
|
|
22
|
The challenge of HIV-1 subtype diversity.
|
N Engl J Med
|
2008
|
1.28
|
|
23
|
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.
|
J Clin Endocrinol Metab
|
2009
|
1.16
|
|
24
|
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
|
J Infect Dis
|
2004
|
1.12
|
|
25
|
Antiretroviral treatment as prevention.
|
N Engl J Med
|
2011
|
1.12
|
|
26
|
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.
|
Stat Commun Infect Dis
|
2011
|
1.06
|
|
27
|
Acceptability of male circumcision for the prevention of HIV among high-risk heterosexual men in Thailand.
|
Sex Transm Dis
|
2010
|
1.05
|
|
28
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2007
|
1.05
|
|
29
|
Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.
|
PLoS One
|
2011
|
1.04
|
|
30
|
Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.
|
AIDS Res Hum Retroviruses
|
2009
|
1.02
|
|
31
|
Patents versus patients? Antiretroviral therapy in India.
|
N Engl J Med
|
2005
|
0.95
|
|
32
|
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
|
Antimicrob Agents Chemother
|
2003
|
0.95
|
|
33
|
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.
|
AIDS Res Hum Retroviruses
|
2010
|
0.93
|
|
34
|
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
Top HIV Med
|
2009
|
0.93
|
|
35
|
Lessons drawn from recent HIV vaccine efficacy trials.
|
J Acquir Immune Defic Syndr
|
2010
|
0.92
|
|
36
|
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.
|
HIV Clin Trials
|
2013
|
0.91
|
|
37
|
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
|
AIDS
|
2002
|
0.89
|
|
38
|
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.
|
AIDS Res Hum Retroviruses
|
2013
|
0.87
|
|
39
|
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.
|
J Clin Microbiol
|
2002
|
0.87
|
|
40
|
Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence.
|
AIDS Patient Care STDS
|
2014
|
0.86
|
|
41
|
CROI 2013: Advances in antiretroviral therapy.
|
Top Antivir Med
|
2013
|
0.85
|
|
42
|
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
|
Antivir Ther
|
2006
|
0.84
|
|
43
|
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
|
Clin Pharmacol Ther
|
2002
|
0.83
|
|
44
|
Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.
|
AIDS Res Hum Retroviruses
|
2011
|
0.83
|
|
45
|
Single-dose nevirapine and drug resistance: the more you look, the more you find.
|
J Infect Dis
|
2005
|
0.82
|
|
46
|
The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
|
J Med Virol
|
2009
|
0.82
|
|
47
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2010
|
0.82
|
|
48
|
207-nm UV light - a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies.
|
PLoS One
|
2013
|
0.81
|
|
49
|
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load.
|
Clin Infect Dis
|
2009
|
0.80
|
|
50
|
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.
|
J Acquir Immune Defic Syndr
|
2016
|
0.80
|
|
51
|
Advances in antiretroviral therapy.
|
Top Antivir Med
|
2012
|
0.79
|
|
52
|
Translational research insights from completed HIV vaccine efficacy trials.
|
J Acquir Immune Defic Syndr
|
2013
|
0.78
|
|
53
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2009
|
0.78
|
|
54
|
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
|
Top HIV Med
|
2008
|
0.77
|
|
55
|
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
|
Top HIV Med
|
2003
|
0.76
|
|
56
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2005
|
0.75
|
|
57
|
Advances in antiretroviral therapy.
|
Top Antivir Med
|
2011
|
0.75
|
|
58
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2006
|
0.75
|
|
59
|
Advances in antiretroviral therapy.
|
Top HIV Med
|
2003
|
0.75
|
|
60
|
Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA.
|
Top HIV Med
|
2004
|
0.75
|
|
61
|
Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|